HOPHF (Hemogenyx Pharmaceuticals) ROE % Adjusted to Book Value: -314.25% (As of Dec. 2025)


HOPHF Hemogenyx Pharmaceuticals PLC HOPHF
31 GF Score
Price $2.33
! 2 Warning Signs
View Full Analysis

What is Hemogenyx Pharmaceuticals ROE % Adjusted to Book Value?

Hemogenyx Pharmaceuticals HOPHF 31 ROE % Adjusted to Book Value is -314.25% as of Dec. 2025. GuruFocus rates HOPHF with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Hemogenyx Pharmaceuticals's ROE % for the quarter that ended in Dec. 2025 was -2,762.26%. Hemogenyx Pharmaceuticals's PB Ratio for the quarter that ended in Dec. 2025 was 8.79. Hemogenyx Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -314.25%.

Hemogenyx Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Hemogenyx Pharmaceuticals ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Hemogenyx Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemogenyx Pharmaceuticals ROE % Adjusted to Book Value Chart

Hemogenyx Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -42.65 -18.82 -17.01 -78.88 -108.70

Hemogenyx Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.11 -13.93 -73.60 0.00 -314.25

HOPHF vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemogenyx Pharmaceuticals ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Hemogenyx Pharmaceuticals's ROE % Adjusted to Book Value falls into.


HOPHF
31GF Score
Hemogenyx Pharmaceuticals PLC HOPHF
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemogenyx Pharmaceuticals ROE % Adjusted to Book Value Calculation

Hemogenyx Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-955.47% / 8.79
=-108.70%

Hemogenyx Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-2,762.26% / 8.79
=-314.25%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -314.25% mean?
Hemogenyx Pharmaceuticals (HOPHF) has a ROE % Adjusted to Book Value of -314.25% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Hemogenyx Pharmaceuticals and its competitors.
Is Hemogenyx Pharmaceuticals' ROE % Adjusted to Book Value too high?
Hemogenyx Pharmaceuticals' current ROE % Adjusted to Book Value is -314.25%. Overall, Hemogenyx Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Hemogenyx Pharmaceuticals' ROE % Adjusted to Book Value compare to VRTX and REGN?
Hemogenyx Pharmaceuticals' ROE % Adjusted to Book Value of -314.25% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Hemogenyx Pharmaceuticals and its competitors. Hemogenyx Pharmaceuticals's current ROE % Adjusted to Book Value is -314.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemogenyx Pharmaceuticals stock overvalued right now?
Hemogenyx Pharmaceuticals (HOPHF) has a current ROE % Adjusted to Book Value of -314.25%. The current ROE % Adjusted to Book Value is -314.25%. Hemogenyx Pharmaceuticals' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Hemogenyx Pharmaceuticals (HOPHF), the current ROE % Adjusted to Book Value is -314.25% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemogenyx Pharmaceuticals Business Description

Other Exchanges HEMO:UK
Address 6 Heddon Street, London, GBR, W1B 4BT
Hemogenyx Pharmaceuticals PLC is clinical-stage biotechnology focused on the discovery, development and commercialisation of treatments relating to the treatment of blood cancers, certain solid cancers, autoimmune diseases, and viral infections. The products under development are designed to address a range of problems that occur with current standard of care treatments. The Group has one reportable segment, the discovery, development, and commercialisation of treatments relating to blood and immune system disorders and viral infections, and administrative functions in the United Kingdom. It has its presence in United Kingdom; and United States.
31GF Score

Get the complete analysis for HOPHF

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.33
Price